Lung cancer is usually suspected in individuals who have abnormal chest radiograph findings or have symptoms caused from either local or systemic meanings of the tumor.

Lung cancer is usually suspected in individuals who have abnormal chest radiograph findings or have symptoms caused from either local or systemic meanings of the tumor. The regularity of diagnosis of suspected lung cancer hangs on the type of lung cancer (ie, small solitary abode; squalid lung cancer or non-small confined apartment lung cancer), the size and location of the primary tumor, the vicinity of metastasis, and the overall clinical status of the patient. Achieving a diagnosis and staging are usually done in design because the most efficient way to make a diagnosis frequently is dictated by the stage of the cancer. The best order of succession of studies and interventions in a particular patient involves careful common-sense of the probable reliability of a number of presumptive diagnostic issues, in the way that as to maximize the sensitivity and to avoid performing multiple or unnecessary invasive proceedings In this article, we consider all manner of clinical presentations of lung cancer in light of generally available diagnostic procedures. Published data supporting a particular diagnostic approach is weighed based in succession the quality of the benefit as well as the estimated toil benefit. Recommendations are graded in bourns of strength to provide clinicians with guidance as to the mostly efficient and approach to the diagnosis of lung cancer in individual patients.

solution words: bronchoscopy; lung neoplasm; sensitivity; specificity; sputum cytology; transthoracic needle aspiration

Abbreviations: FDG = [sup.18]F-2-fluoro-2-deoxy-D-glucose; FN = false negative; FNA = fine needle aspirate; NSCLC = non-small enclosed space lung cancer; PET = positron emission tomography; SCLC = small lonely dwelling lung cancer; TBNA = transbronchial needle aspiration; TTNA = transthoracic needle aspiration

**********

The radiographic findings and clinical presentation usually allow a presumptive differentiation between small lonely dwelling lung cancer (SCLC) and non-SCLC (NSCLC) Massive lymphadenopathy and direct mediastinal invasion are well-recognized phenomena in SCLC (12) A mass in, or adjacent to, the hilum is a particular characteristic of SCLC and is seen in about 78% of cases. (12) Not infrequently, patients with SCLC instant with paraneoplastic syndromes. (3) These include the syndrome of inappropriate antidiuretic hormone, ectopic adrenocorticotrophic hormone production, and the Lambert-Eaton syndrome If SCLC is suspected, the diagnosis should be achieved by dint of whatever means is easiest (ie, sputum cytology, thoracentesis if an accessible pleural effusion is quick in emergencies fine needle aspirate [FNA] of a supraclavicular node or metastatic site, bronchoscopy with or without transbronchial needle aspiration [TBNA] of mediastinal nodes or submucosal process) If the diagnosis of SCLC is established in succession a biopsy of the primary lesion, the distinction between limited or extensive disease then is made radiographically.

In patients who are suspected of having NSCLC the manner of achieving a diagnosis is usually dictated by dint of the presumed stage of the disease. Patients with suspected lung cancer who ready with a pleural effusion should go through thoracentesis first in order to differentiate between a malignant effusion (ie, united due to malignant involvement of the pleura) and a paramalignant effusion (ie, single in kind due to other factors of the like kind as lymphatic blockade, atelectasis, or hypoproteinemia). Distinction between the brace is important because the finding of malignant solitary abode; squalids in the pleural fluid alters the stage and treatment of the particular patient. Because pleural metastases are more everyday in the visceral pleura (4) and wait to be focal when there is involvement of the parietal pleura, pleural fluid cytology is a more sensitive diagnostic standard than percutaneous pleural biopsy, the latter being a blind sampling management (5-7) When three separate pleural fluid specimens from a patient with malignant pleural disease are submitted to an experienced cytologist, single should expect a positive diagnosis in about 80% of patients. (78) Percutaneous, clos pleural biopsy is reported (6) to be diagnostic for malignancy in about 50% of cases. Thoracoscopic biopsy of the pleura is safe and can provide a definitive diagnosis with a high step of accuracy and minimal risk to the patient. (910) The reported sensitivity rate is 080 to 1 the specificity rate is 1 and the negative predictive value is 093 (911-13) False-negative exhibition results are more common with mesothelioma than with primary lung carcinoma. (11)

Patients with metastatic NSCLC (stage IV disease) usually current with constitutional symptoms (ie, fatigue and weight loss) organ-specific symptoms (ie, bone pain and neurologic symptoms), and/or abnormal laboratory findings (ie, anemia, elevated alkaline phosphatase on a levels and/or elevated liver enzyme levels) In many of these patients, a FNA or a needle biopsy of a site of metastasis exhibits the most efficient way one as well as the other to make a diagnosis and to confirm the stage. In a certain number of cases, however, the metastatic site may be technically difficult to biopsy. If metastatic disease can be predicted with a high measure of accuracy on the basis of radiographic findings (ie, multiple brain, liver, or bone lesions), it may be more efficient to achieve a diagnosis of the primary lung lesion according to whatever method is easiest for the patient (ie, sputum cytology, bronchoscopy or transthoracic needle aspiration [TTNA]). This decision must be made by way of weighing the technical considerations involved in each approach as well as the reliability of diagnosing an extrathoracic lesion as a site of metastasis based onward radiographic appearances alone (see the article onward clinical/noninvasive staging elsewhere in this supplement) A joint decision among the radiologist, the pulmonologist, and the medical or radiation oncologist is the desirable approach.

...